ArticleJGH open : an open access journal of gastroenterology and hepatology2022
Chronic steroid use: An overlooked impact on patients with inflammatory bowel disease.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- The effects of steroid treatment on osteoporosis in patients with inflammatory bowel disease: A systematic review and meta-analysis.Medicine · 2026Pooled it
- Prevalence of metabolic syndrome in patients with inflammatory bowel disease: a meta-analysis on a global scale.Journal of health, population, and nutrition · 2025Pooled it
- Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence.Frontiers in medicine · 2025Pooled it
- Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial.Journal of Crohn's & colitis · 2026Trial
- Effects of Age on Inflammatory Bowel Disease Presentation and Management in Older Adults.Digestive diseases and sciences · 2026Review
- Optimising clinical trial design choices in inflammatory bowel disease.BMJ open gastroenterology · 2026Review
- Rising Burden and Clinical Impact of Metabolic Syndrome in Inflammatory Bowel Disease: A Real-World Cohort Study.United European gastroenterology journal · 2026Article
- Inflammatory Bowel Disease and Risk of More than 1,500 Comorbidities: A Disease-wide Prediagnostic and Postdiagnostic Phenomic Association Study.The American journal of gastroenterology · 2026Article
- Immune-Mediated Colitis Induced by Immune Checkpoint Inhibitors: Pathophysiology, Clinical Management, and the Emerging Role of Fecal Microbiota Transplantation.Biomedicines · 2026Review
- Use of Janus Kinase Inhibitor Upadacitinib in Microscopic Colitis.ACG case reports journal · 2026Article
- Antibiotic consumption and medication cost in diabetic patients: Insights from Iran health insurance organization (IHIO) claims data.PloS one · 2026Article
- Upadacitinib induction therapy in Crohn' s disease: a retrospective real-world study in biologic-refractory patients.BMC gastroenterology · 2025Article
- Anti-IBD activity of Eleusine indica through inhibition of TNF-alpha and p38 MAPK expression.Inflammopharmacology · 2025Article
- Protective effects of dill fruit against acute acetic acid-induced ulcerative colitis by reducing inflammation and oxidative stress in rats.Physiological reports · 2025Article
- Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A practical approach to positioning therapies in ulcerative colitis.Journal of the Canadian Association of Gastroenterology · 2025Article
- A targeted review of clinical outcomes of advanced IBD therapies in Latin America.Therapeutic advances in gastroenterology · 2025Review
- Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition.Intestinal research · 2025Review
- Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn's Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies.Diseases (Basel, Switzerland) · 2024Review
- Medication Burden Before and After Prescription of Biologics in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Steroids have long been used in inducing remission of inflammatory bowel disease (IBD). Chronic use, defined as therapy greater than 3 months, has been implicated in complications including increased hospital length of stay (LOS), infections, and even death. In our retrospective study, we aim to identify the complications of chronic steroid use in patients with IBD. Methods: The fourth quarter of 2015-2019 National Inpatient Sample (NIS) was used in this study. International Classification of Diseases (ICD-10) codes were used to identify patients with a diagnosis of IBD and chronic steroid use. Adverse outcomes of chronic steroid use in IBD patients were analyzed, such as osteoporosis, opportunistic infections, mortality rate, and LOS. Cohorts were weighted using an algorithm provided by the NIS allowing for accurate national estimates. Results: A total of 283 970 patients had a diagnosis of IBD. Of those, 18 030 patients had concurrent chronic steroid use. Racial disparities existed, with 77.4% White, 12.7% Black, and 6.0% Hispanic. Patients with a history of IBD and chronic steroid use were found to have higher odds of developing osteoporosis, opportunistic infections, and acute thromboembolic events but did not have higher odds of mortality. Conclusion: There is much controversy about whether IBD patients should be on chronic steroids for maintenance therapy and this study highlights the importance of this decision as patients on chronic steroid use had higher odds of developing adverse effects. These results stress the importance of monitoring patients on steroids and avoiding chronic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.